Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue: +36.3%
EPS: +36.0%
Free cash flow: +3.85%
Total debt: +0.06%

Quarter to September 2026, against a year earlier

905.02 2.12 +0.23%

Follow REGN

Alert me

Market cap: $93.4B
P/E: 19.3×
Fwd P/E: 19.2×
Dividend yield: 0.41%
F-score: 5/9
Altman Z: 7.49
Beneish M: −2.53
Dividend safety: 77/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

	Older periods	Dec '25	Mar '26	Jun '26	Sep '26
P/E ratio Full definition →	+8 more quarters Free account	17.90	18.17	14.88	16.14
P/S ratio Full definition →		5.63	5.39	4.13	4.56
P/FCF ratio Full definition →		21.44	21.20	17.93	21.26
P/Operating CF Full definition →		68.97	74.48	78.84	43.24
P/B ratio Full definition →		2.58	2.56	2.02	2.30
Price to Tangible BV Full definition →		2.69	2.67	2.11	2.40
EV/Sales Full definition →		5.32	5.03	3.84	3.70
EV/EBITDA Full definition →		18.52	18.01	13.63	11.62
EV/Operating CF Full definition →		15.33	14.98	12.73	12.89
EV/FCF Full definition →		20.27	19.81	16.67	17.22
Quick Ratio Full definition →		3.28	2.84	2.63	3.66
Current Ratio Full definition →		4.13	3.57	3.34	4.06
Net Debt/EBITDA Full definition →		(5.76)	(8.83)	(4.24)	(7.45)
Debt/Assets Full definition →		6.67%	4.86%	4.76%	6.10%
Debt/Equity Full definition →		0.09	0.06	0.06	0.08
Asset Turnover Full definition →		0.37	0.38	0.39	0.40
Operating CF/Net income Full definition →		1.39	1.48	0.63	0.92
Capex/Depreciation Full definition →		(2.00)	(2.27)	(2.35)	(2.95)
Interest Coverage Full definition →		72.12	49.84	117.59	193.23
Research and Development Expense of Revenue Full definition →		41.86%	42.81%	38.03%	35.08%
Selling, General and Administrative Expense of Revenue Full definition →		19.95%	17.96%	15.43%	13.25%
Intangible Assets out of Total Assets Full definition →		0.03	0.03	0.03	0.03
Share Based Compensation of Revenue Full definition →		6.42%	7.14%	5.66%	5.00%
Graham Net Nets Full definition →		0.11	0.11	0.13	0.24
Graham Number Full definition →		538.44	537.71	539.34	590.07
Earnings Yield Full definition →		5.59%	5.50%	6.72%	6.20%
Free Cash Flow Yield Full definition →		4.66%	4.72%	5.58%	4.70%
Revenue per Share Full definition →		37.13	34.67	41.74	50.30
Operating CF per Share Full definition →		11.19	10.37	7.91	17.54
Capex per Share Full definition →		(2.78)	(2.69)	(2.83)	(3.51)
Free Cash Flow per Share Full definition →		8.41	7.69	5.08	14.03
Cash per Share Full definition →		82.27	84.17	77.77	185.43
Shareholders Equity per Share Full definition →		298.82	302.15	308.48	329.39
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		298.82	302.15	308.48	329.39
Free Cash Flow Full definition →		880.00	799.40	521.80	1,426.90
Working Capital Full definition →		13,653.50	13,101.50	12,915.40	22,102.00
Capital Expenditures Full definition →		(290.70)	(279.50)	(291.20)	(356.50)
Net Current Asset Value Full definition →		8,720.10	8,764.00	8,426.80	18,425.00
EV/EBIT Full definition →		21.34	20.69	15.51	12.84
Capex to Sales Full definition →		0.07	0.08	0.07	0.07
Price to Operating Income Full definition →		22.57	22.14	16.68	15.85
Other line items
Average Receivables Full definition →		5,976.50	5,646.00	6,087.70	6,632.85
Average Payables Full definition →		864.25	866.30	941.60	4,066.75
Average Inventory Full definition →		3,144.05	3,148.00	3,144.95	3,074.50
Average Assets Full definition →		39,159.05	39,207.00	39,974.90	42,287.30
Average Common Equity Full definition →		30,305.25	30,405.60	30,825.15	32,228.15

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026

Stockrow Weekly